Adicet Bio Inc (ACET) - Net Assets
Based on the latest financial reports, Adicet Bio Inc (ACET) has net assets worth $140.06 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($169.38 Million) and total liabilities ($29.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Adicet Bio Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $140.06 Million |
| % of Total Assets | 82.69% |
| Annual Growth Rate | 1.5% |
| 5-Year Change | -47.48% |
| 10-Year Change | -47.7% |
| Growth Volatility | 69.89 |
Adicet Bio Inc - Net Assets Trend (2008–2025)
This chart illustrates how Adicet Bio Inc's net assets have evolved over time, based on quarterly financial data. See ACET defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Adicet Bio Inc (2008–2025)
The table below shows the annual net assets of Adicet Bio Inc from 2008 to 2025. For live valuation and market cap data, see ACET market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $159.21 Million | -14.68% |
| 2024-12-31 | $186.61 Million | +9.66% |
| 2023-12-31 | $170.18 Million | -41.79% |
| 2022-12-31 | $292.34 Million | -3.56% |
| 2021-12-31 | $303.13 Million | +176.01% |
| 2020-12-31 | $109.83 Million | +281.94% |
| 2019-12-31 | $-60.37 Million | -157.93% |
| 2018-12-31 | $104.20 Million | +109.70% |
| 2017-12-31 | $49.69 Million | -83.68% |
| 2016-12-31 | $304.44 Million | +19.76% |
| 2015-12-31 | $254.21 Million | +8.83% |
| 2014-12-31 | $233.58 Million | +20.01% |
| 2013-12-31 | $194.64 Million | +15.86% |
| 2012-12-31 | $168.00 Million | +16.55% |
| 2011-12-31 | $144.15 Million | +15.92% |
| 2010-12-31 | $124.35 Million | -0.82% |
| 2009-12-31 | $125.38 Million | +1.39% |
| 2008-12-31 | $123.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Adicet Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 851.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.01% |
| Other Comprehensive Income | $102.00K | 0.06% |
| Other Components | $773.79 Million | 486.02% |
| Total Equity | $159.21 Million | 100.00% |
Adicet Bio Inc Competitors by Market Cap
The table below lists competitors of Adicet Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lee Feed Mill Public Company Limited
BK:LEE
|
$70.59 Million |
|
GrowGeneration Corp
NASDAQ:GRWG
|
$70.62 Million |
|
Betamek Bhd
KLSE:0263
|
$70.62 Million |
|
Adyton Resources Corp
V:ADY
|
$70.63 Million |
|
Kingstate Electronics
TWO:3206
|
$70.54 Million |
|
Nordisk Bergteknik AB Series B
ST:NORB-B
|
$70.53 Million |
|
Aeye Inc
NASDAQ:LIDR
|
$70.51 Million |
|
Manba Finance Ltd
NSE:MANBA
|
$70.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Adicet Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 186,609,000 to 159,210,000, a change of -27,399,000 (-14.7%).
- Net loss of 116,803,000 reduced equity.
- New share issuances of 75,172,000 increased equity.
- Other comprehensive income increased equity by 86,000.
- Other factors increased equity by 14,146,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-116.80 Million | -73.36% |
| Share Issuances | $75.17 Million | +47.22% |
| Other Comprehensive Income | $86.00K | +0.05% |
| Other Changes | $14.15 Million | +8.89% |
| Total Change | $- | -14.68% |
Book Value vs Market Value Analysis
This analysis compares Adicet Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.35x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.08x to 0.35x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $103.53 | $8.10 | x |
| 2009-12-31 | $103.64 | $8.10 | x |
| 2010-12-31 | $101.23 | $8.10 | x |
| 2011-12-31 | $112.68 | $8.10 | x |
| 2012-12-31 | $114.58 | $8.10 | x |
| 2013-12-31 | $129.66 | $8.10 | x |
| 2014-12-31 | $155.60 | $8.10 | x |
| 2015-12-31 | $162.74 | $8.10 | x |
| 2016-12-31 | $173.68 | $8.10 | x |
| 2017-12-31 | $29.47 | $8.10 | x |
| 2018-12-31 | $55.95 | $8.10 | x |
| 2019-12-31 | $-52.04 | $8.10 | x |
| 2020-12-31 | $240.06 | $8.10 | x |
| 2021-12-31 | $156.70 | $8.10 | x |
| 2022-12-31 | $113.86 | $8.10 | x |
| 2023-12-31 | $63.26 | $8.10 | x |
| 2024-12-31 | $33.98 | $8.10 | x |
| 2025-12-31 | $23.10 | $8.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Adicet Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -73.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.21x
- Recent ROE (-73.36%) is below the historical average (-17.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 9.60% | 3.75% | 1.75x | 1.46x | $-567.90K |
| 2009 | 6.10% | 2.67% | 1.70x | 1.34x | $-5.53 Million |
| 2010 | 4.71% | 1.90% | 1.60x | 1.55x | $-7.38 Million |
| 2011 | 5.58% | 2.17% | 1.40x | 1.83x | $-7.11 Million |
| 2012 | 10.11% | 3.82% | 1.48x | 1.78x | $180.70K |
| 2013 | 11.47% | 4.47% | 1.54x | 1.66x | $2.86 Million |
| 2014 | 9.56% | 4.47% | 1.07x | 2.00x | $-1.03 Million |
| 2015 | 11.41% | 5.68% | 1.04x | 1.93x | $3.58 Million |
| 2016 | 0.00% | 0.00% | 1.01x | 1.78x | $-30.45 Million |
| 2017 | -67.98% | -6.05% | 10.12x | 1.11x | $-38.75 Million |
| 2018 | -8.92% | -113.67% | 0.07x | 1.06x | $-19.72 Million |
| 2019 | 0.00% | -2827.94% | 0.01x | 0.00x | $-22.10 Million |
| 2020 | -33.40% | -204.87% | 0.12x | 1.40x | $-47.66 Million |
| 2021 | -20.45% | -637.19% | 0.03x | 1.12x | $-92.31 Million |
| 2022 | -23.87% | -279.27% | 0.08x | 1.13x | $-99.02 Million |
| 2023 | -83.83% | 0.00% | 0.00x | 1.22x | $-159.68 Million |
| 2024 | -62.76% | 0.00% | 0.00x | 1.18x | $-135.78 Million |
| 2025 | -73.36% | 0.00% | 0.00x | 1.21x | $-132.72 Million |
Industry Comparison
This section compares Adicet Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Adicet Bio Inc (ACET) | $140.06 Million | 9.60% | 0.21x | $70.58 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops … Read more